Skip to content

Study Details

BI 1015550: A Study Drug to Improve Lung Function for People with Idiopathic Pulmonary Fibrosis (IPF)

(IRB#: IRB_00158413)

Idiopathic Pulmonary Fibrosis (IPF) is a disease that causes the lungs to become scarred and breathing difficult. BI 1015550 is a study drug to help people with IPF. Research is needed to know the safety, effectiveness, and side effects BI 1015550. The information we gain may aid future patients.

I AM INTERESTED

  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18-40 years old
  • IPF diagnosis
  • On stable treatment with nintedanib or pirfenidone for at least 12 weeks, or not on treatment with either nintedanib or pirfenidone for at least 8 weeks before starting the study

Exclusion Criteria

  • Acute IPF exacerbation (your disease declines suddenly and quickly) within 3 months prior to and/or during the screening period
  • Human immunodeficiency virus (HIV) and viral hepatitis
  • Confirmed infection with SARS-CoV-2 (COVID-19) and not fully recovered within 4 weeks before starting the study
  • Major surgery within 6 weeks prior to or planned during the study, e.g. hip replacement.
  • Women who are pregnant, nursing, or who plan to become pregnant while in the study

Will I be paid for my time?

Yes

For more information contact:

Cassie Larsen

cassie.larsen@hsc.utah.edu

  801-581-5811

IRB#: IRB_00158413

PI: Mary Beth Scholand

Department: PULMONARY

Approval Date: 2023-02-08 07:00:00

Specialties: Pulmonary

Last Updated: 6/8/23